Delivery of medication to the human eye is an integral part of medical treatment. Ophthalmic drug delivery is one of the most interesting and challenging endeavours facing the pharmaceutical scientist. The anatomy, physiology and biochemistry of the eye render this organ impervious to foreign substances. Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis. Ketorolac tromethamine given systemically does not cause pupil constriction. An acetic acid derivative ketorolac tromethamine has found its applicability in both gram positive and gram negative bacterial ocular infection and used commonly associated with multiple doses. Ophthalmic medication stored in multiple dose containers is required by the U.S. Food and Drug Administration to contain a preservative so that patients are provided with microbe free medication. Benzalkonium chloride in concentrations from 0.1% to 0.0001% induced dose-dependent growth arrest and conjunctiva epithelial cell death, either delayed or immediately after administration. In such case, a preservative Benzalkonium chloride must be used within reasonable bound. Benzalkonium chloride can provide more help than harm. Hence the present study focusing on to  formulate a formulation for ketorolac tromethamine(0.5%) ophthalmic solution using different concentration of  Benzalkonium chloride as preservative.

Keywords: Ketorolac tromethamine, Ophthalmic, Benzalkonium chloride, Conjunctiva